Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Fintel reports that on October 7, 2024, Wells Fargo upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

The projected annual revenue for Gilead Sciences is 26,909MM ... first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Strategic highlights ? solid progress on both strategic and operational priorities  Increased momentum in programmable networks, mobile network contract wins in multiple markets.  Global supply of ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, ...

PORTLAND, CA, UNITED STATES, October 7, 2024 /EINPresswire / -- According to the report, the global cancer gene therapy <a target=_blank href=ht ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...